乳癌治疗市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024 年全球乳癌治疗市场规模为 315 亿美元，预计到 2034 年将以 8.5% 的复合年增长率成长至 713 亿美元。市场成长归因于多种因素：乳癌高发生率、早期发现和治疗意识的提高、以及政府和非营利筛检计画的支持力度加大。随着筛检的增加和更多病例在早期阶段被发现，对有效治疗方案的需求上升，从而支持了市场的发展势头。此外，人口老化、肥胖、久坐生活方式和都市化进程的加速也导致乳癌盛行率上升。发展中市场医疗服务可近性的扩大进一步促进了治疗的应用。标靶治疗、荷尔蒙疗法和免疫疗法等个人化医疗的进展正在改善治疗效果并推动市场扩张。

乳癌治疗涵盖一系列旨在控制病情进展、预防復发和提​​高存活率的疗法。默克、阿斯特捷利康、诺华、辉瑞和罗氏等领先製药公司正大力投资研发，尤其註重精准肿瘤学和生物标记驱动疗法。政府筛选计画和宣传活动正在加速早期诊断，进而推动对先进疗法的需求。新兴经济体医疗基础设施的建设和报销改革使得更广泛的治疗可近性成为可能。转向更具针对性的干预措施（包括单株抗体、小分子抑制剂和免疫肿瘤药物）的转变正在提高疗效并减少副作用，从而进一步推动其应用。

2024年，标靶疗法的市场规模达到214亿美元，占据主导地位，这得益于其能够靶向癌症相关生物标记且不良反应较少。抗体-药物偶联物、HER2抑制剂和PARP抑制剂等剂型在早期和晚期治疗方案中被广泛采用。 HER2低亚型疗法的创新以及AI引导的患者分层技术，巩固了其在该领域的市场领先地位。

2024年，侵袭性乳癌占78.9%的市场份额，是最常见的乳癌类型。光是浸润性乳管癌就约占所有侵袭性病例的80%，约占乳癌诊断的55%。由于侵袭性乳癌具有侵袭性且可能转移至导管外，因此需要多种治疗方法，包括标靶药物、荷尔蒙调节剂（例如选择性雌激素受体调节剂SERM）、化疗和免疫疗法，从而推动了强劲的临床需求。

2024年，北美乳癌治疗市场占40.9%的市场份额，其中美国和加拿大占据主导地位。先进的医疗基础设施、高度的早期检测意识、强大的肿瘤学研究投入以及优惠的报销制度推动了治疗方案的采用。该地区受益于快速的监管审批、专利疗法的高渗透率以及新兴治疗模式的广泛应用，巩固了其在全球乳癌治疗领域的领先地位。

辉瑞、罗氏、默克、阿斯特捷利康、诺华和礼来等主要公司正在塑造这一行业，它们推动创新和全球影响力。领先的製药公司正专注于按分子亚型对患者进行分层，从而透过伴随诊断优化精准标靶治疗。许多公司正在拓展抗体药物偶联物、双特异性抗体、CDK4/6抑制剂和免疫疗法组合等新型疗法的研发管线，以增强产品组合深度。策略性收购、授权协议以及与生技公司的策略合作，加速了创新化合物和新兴研发人才的取得。透过与区域分销商和医疗保健系统的合作，公司正在向新兴市场进行全球扩张。此外，公司还投资于真实世界研究和基于价值的成果，以支持报销谈判。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 全球乳癌发生率上升
    • 标靶治疗和免疫治疗的进展
    • 提高认识和早期检测计划
    • 个人化医疗和生物标记检测的需求不断增长
  • 产业陷阱与挑战
    • 治疗费用高昂
    • 治疗的副作用和毒性
  • 市场机会
    • 新型疗法的开发
    • 合作与策略伙伴关係
• 成长潜力分析
• 技术格局
  • 当前的技术趋势
  • 新兴技术
• 管道分析
• 监管格局
• 未来市场趋势
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 关键进展
  • 併购
  • 伙伴关係与协作
  • 新产品发布

第五章：市场估计与预测：按疗法，2021 - 2034 年

• 主要趋势
• 标靶治疗
• 荷尔蒙疗法
• 化疗
• 免疫疗法

第六章：市场估计与预测：按癌症类型，2021 - 2034 年

• 主要趋势
• 乳管原位癌（DCIS）
• 侵袭性乳癌
  • 浸润性乳管癌（IDC）
    • 荷尔蒙受体
    • HER2+
    • 三阴性乳癌（TNBC）
    • 其他浸润性乳管癌 (IDC) 类型
  • 浸润性小叶癌（ILC）

第七章：市场估计与预测：按管理路线，2021 - 2034 年

• 主要趋势
• 口服
• 肠外

第八章：市场估计与预测：按年龄组，2021 - 2034 年

• 主要趋势
• 20 - 39
• 40 - 59
• 60岁以上

第九章：市场估计与预测：依最终用途，2021 - 2034 年

• 主要趋势
• 医院
• 肿瘤诊所
• 其他最终用途

第十章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：公司简介

• Amgen
• AstraZeneca
• Eisai
• Eli Lilly and Company
• F. Hoffmann La Roche
• GE HealthCare
• Gilead Sciences
• Macrogenics
• Merck
• Novartis
• Pfizer
• Sun Pharmaceutical

The Global Breast Cancer Therapeutics Market was valued at USD 31.5 billion in 2024 and is estimated to grow at a CAGR of 8.5% to reach USD 71.3 billion by 2034. The market growth is attributed to a combination of factors: high incidence of breast cancer, expanded awareness of early detection and treatment, and rising support from government and nonprofit screening initiatives. As screening increases and more cases are identified at earlier stages, demand for effective treatment options rises, supporting the market's momentum. Also, rising rates of aging populations, obesity, sedentary lifestyles, and urbanization are contributing to higher breast cancer prevalence. Expanded health access in developing markets further boosts therapy uptake. Advances in personalized medicine-such as targeted treatments, hormone therapy, and immunotherapy-are enhancing outcomes and fueling market expansion.

Breast cancer therapeutics encompass a spectrum of treatments aimed at controlling disease progression, preventing recurrence, and improving survival. Leading pharmaceutical firms such as Merck, AstraZeneca, Novartis, Pfizer, and F. Hoffmann-La Roche are investing heavily in R&D, particularly focusing on precision oncology and biomarker-driven therapies. Government screening programs and awareness campaigns are accelerating early diagnosis, which in turn drives demand for advanced treatments. Growth in emerging economies' healthcare infrastructure and reimbursement reforms enabling broader access. The shift toward more targeted interventions-including monoclonal antibodies, small-molecule inhibitors, and immuno-oncology agents-is improving efficacy while reducing side effects, further boosting adoption.

The targeted therapies generated USD 21.4 billion in 2024, dominating due to their ability to target cancer-associated biomarkers with fewer adverse reactions. Formats such as antibody-drug conjugates, HER2 inhibitors, and PARP inhibitors are widely adopted across both early- and late-stage treatment protocols. Innovations in HER2 low subtype therapies and AI guided patient stratification support continued market leadership of this category.

The invasive breast cancer segment held 78.9% share in 2024 and is the most prevalent form of disease. Invasive ductal carcinoma alone accounts for about 80% of all invasive cases and roughly 55% of breast cancer diagnoses. Because of its aggressive nature and potential to metastasize beyond the ducts, invasive breast cancer demands broad treatment approaches, including targeted agents, hormone modulators such as SERMs, chemotherapy, and immunotherapies, driving strong clinical demand.

North America Breast Cancer Therapeutics Market held 40.9% share in 2024, with the United States and Canada leading. Advanced healthcare infrastructure, high early detection awareness, strong oncology research investment, and favorable reimbursement systems drove therapeutic adoption. This region benefits from rapid regulatory approvals, high proprietary therapy penetration, and widespread uptake of emerging treatment modalities, reinforcing its leadership in the global breast cancer therapeutics landscape.

Major companies shaping this industry include Pfizer, F. Hoffmann-La Roche, Merck, AstraZeneca, Novartis, and Eli Lilly, driving innovation and global reach. Leading pharmaceutical players are focusing heavily on patient stratification by molecular subtype, enabling precision-targeted therapies optimized with companion diagnostics. Many firms are expanding pipelines in novel modalities such as antibody-drug conjugates, bispecific antibodies, CDK4/6 inhibitors, and immunotherapy combinations to strengthen portfolio depth. Strategic acquisitions, licensing agreements, and strategic partnerships with biotech firms accelerate access to innovative compounds and emerging R&D talent. Global expansion into emerging markets is being achieved through collaborations with regional distributors and healthcare systems. Additionally, firms invest in real-world studies and value-based outcomes to support reimbursement negotiations.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Therapy
  • 2.2.3 Cancer type
  • 2.2.4 Route of administration
  • 2.2.5 Age group
  • 2.2.6 End use
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising global incidence of breast cancer
    • 3.2.1.2 Advancements in targeted and immunotherapies
    • 3.2.1.3 Growing awareness and early detection programs
    • 3.2.1.4 Increasing demand for personalized medicine and biomarker testing
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Side effects and toxicity of treatments
  • 3.2.3 Market opportunities
    • 3.2.3.1 Development of novel therapeutics
    • 3.2.3.2 Collaborations and strategic partnerships
• 3.3 Growth potential analysis
• 3.4 Technology landscape
  • 3.4.1 Current technological trends
  • 3.4.2 Emerging technologies
• 3.5 Pipeline analysis
• 3.6 Regulatory landscape
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Key developments
  • 4.5.1 Merger and acquisition
  • 4.5.2 Partnership and collaboration
  • 4.5.3 New product launches

Chapter 5 Market Estimates and Forecast, By Therapy, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Targeted therapy
• 5.3 Hormonal therapy
• 5.4 Chemotherapy
• 5.5 Immunotherapy

Chapter 6 Market Estimates and Forecast, By Cancer Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Ductal carcinoma in situ (DCIS)
• 6.3 Invasive breast cancer
  • 6.3.1 Invasive ductal carcinoma (IDC)
    • 6.3.1.1 Hormone receptor
    • 6.3.1.2 HER2+
    • 6.3.1.3 Triple-negative breast cancer (TNBC)
    • 6.3.1.4 Other invasive ductal carcinoma (IDC) types
  • 6.3.2 Invasive lobular carcinoma (ILC)

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Parenteral

Chapter 8 Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 20 - 39
• 8.3 40 - 59
• 8.4 Above 60

Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals
• 9.3 Oncology clinics
• 9.4 Other end use

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Amgen
• 11.2 AstraZeneca
• 11.3 Eisai
• 11.4 Eli Lilly and Company
• 11.5 F. Hoffmann La Roche
• 11.6 GE HealthCare
• 11.7 Gilead Sciences
• 11.8 Macrogenics
• 11.9 Merck
• 11.10 Novartis
• 11.11 Pfizer
• 11.12 Sun Pharmaceutical